i n f l a r x

Loading

Impressum Privacy policy

Contact us

+49 3641 508 180

info@inflarx.de

Address

InflaRx N.V.

Winzerlaer Str. 2, 07745 Jena

Press Releases
Home Investors Press Releases

Press Releases

Filter by Year:

InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum
May 28, 2025
Download PDF read more
InflaRx to Participate in Upcoming Investor Conferences
May 22, 2025
Download PDF read more
InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update
May 07, 2025
Download PDF read more
InflaRx to Report First Quarter 2025 Results on May 7, 2025
Apr 30, 2025
Download PDF read more
InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones
Mar 20, 2025
Download PDF read more
InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting
Mar 07, 2025
Download PDF read more
InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting
Feb 28, 2025
Download PDF read more
InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences
Feb 25, 2025
Download PDF read more
InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
Feb 18, 2025
Download PDF read more
InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
Feb 13, 2025
Download PDF read more
InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants
Feb 13, 2025
Download PDF read more
InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference
Jan 23, 2025
Download PDF read more
InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)
Jan 15, 2025
Download PDF read more
InflaRx Announces Participation in January Events in San Francisco
Jan 07, 2025
Download PDF read more
InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904
Dec 20, 2024
Download PDF read more
InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome
Nov 15, 2024
Download PDF read more
InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update
Nov 08, 2024
Download PDF read more
InflaRx to Report Third Quarter 2024 Results on November 8 and to Participate in the Guggenheim Inaugural Healthcare Innovation Conference on November 11
Oct 31, 2024
Download PDF read more
InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress
Sep 25, 2024
Download PDF read more
InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases
Sep 03, 2024
Download PDF read more
InflaRx Announces Participation in September Investor Events
Aug 27, 2024
Download PDF read more
InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update
Aug 08, 2024
Download PDF read more
InflaRx to Report Second Quarter 2024 Results on August 8, 2024
Aug 01, 2024
Download PDF read more
InflaRx to Present New Preclinical Data on INF904 at the 19th European Meeting on Complement in Human Diseases
Jul 30, 2024
Download PDF read more
InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)
Jun 24, 2024
Download PDF read more
InflaRx Hosts R&D Event Highlighting the Promise of INF904
Jun 05, 2024
Download PDF read more
InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators
May 21, 2024
Download PDF read more
InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update
May 08, 2024
Download PDF read more
InflaRx to Host Virtual R&D Event on June 5 and Report First Quarter 2024 Results on May 8
Apr 30, 2024
Download PDF read more
InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event
Apr 24, 2024
Download PDF read more
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
Mar 21, 2024
Download PDF read more
InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024
Mar 19, 2024
Download PDF read more
InflaRx Appoints Jan Medina as Head of Investor Relations
Feb 22, 2024
Download PDF read more
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
Jan 25, 2024
Download PDF read more
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
Jan 04, 2024
Download PDF read more
InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum
Nov 06, 2023
Download PDF read more
InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update
Nov 01, 2023
Download PDF read more
InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904
Sep 11, 2023
Download PDF read more
InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)
Aug 30, 2023
Download PDF read more
InflaRx Reports Second Quarter 2023 Financial Results & Operating Update
Aug 10, 2023
Download PDF read more
InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer
Jun 28, 2023
Download PDF read more
InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients
Jun 21, 2023
Download PDF read more
InflaRx Reports First Quarter 2023 Financial and Operating Results and Provides Business Update
May 11, 2023
Download PDF read more
InflaRx Announces Closing of the Full Exercise of Greenshoe Option Increasing the Proceeds of the Recently Announced Public Offering of Ordinary Shares to US$46 million
Apr 18, 2023
Download PDF read more
InflaRx Announces Closing of $40 Million Public Offering of Ordinary Shares
Apr 14, 2023
Download PDF read more
InflaRx Announces Public Offering of Ordinary Shares
Apr 11, 2023
Download PDF read more
InflaRx Announces Pricing of $40 Million Public Offering of Ordinary Shares
Apr 11, 2023
Download PDF read more
InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients
Apr 04, 2023
Download PDF read more
InflaRx Reports Full Year 2022 Financial and Operating Results
Mar 22, 2023
Download PDF read more
InflaRx Provides Update on Planned Phase III Study Design in Pyoderma Gangrenosum with Vilobelimab and Status of its EUA Application in Critically Ill COVID-19 Patients
Jan 05, 2023
Download PDF read more
InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connection with Regulatory Filing in China for Anti-C5a-Antibody for Treatment of COVID-19
Dec 21, 2022
Download PDF read more
InflaRx Initiates First-in-Human Study with Small Molecule C5aR Inhibitor INF904
Nov 09, 2022
Download PDF read more
InflaRx Reports Third Quarter 2022 Financial & Operating Results
Nov 09, 2022
Download PDF read more
InflaRx Submits Request for Emergency Use Authorization to US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients
Sep 29, 2022
Download PDF read more
InflaRx to Present at Upcoming Scientific and Investor Conferences
Sep 09, 2022
Download PDF read more
InflaRx Announces Vilobelimab Phase III Results in Critically Ill COVID-19 Patients Published in The Lancet Respiratory Medicine
Sep 08, 2022
Download PDF read more
InflaRx Reports Second Quarter 2022 Financial & Operating Results
Aug 05, 2022
Download PDF read more
InflaRx Announces Plans to Apply for Emergency Use Authorization from the US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients
Jul 26, 2022
Download PDF read more
InflaRx Receives FDA Fast Track Designation for Treatment of Ulcerative Pyoderma Gangrenosum
Jul 06, 2022
Download PDF read more
InflaRx Provides Development Update for Vilobelimab in Pyoderma Gangrenosum and Severe COVID-19
Jun 29, 2022
Download PDF read more
InflaRx to Present at the H.C. Wainwright Global Investment Conference
May 17, 2022
Download PDF read more
InflaRx Reports Third Quarter 2021 Financial & Operating Results
May 12, 2022
Download PDF read more
InflaRx Reports First Quarter 2022 Financial and Operating Results and Provides Strategic Update
May 12, 2022
Download PDF read more
InflaRx Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients
Mar 31, 2022
Download PDF read more
InflaRx Reports Full Year 2021 Financial and Operating Results
Mar 24, 2022
Download PDF read more
InflaRx Receives Corrected Advice Letter from FDA Related to Phase III Program for Vilobelimab in Hidradenitis Suppurativa
Mar 17, 2022
Download PDF read more
InflaRx Announces Vilobelimab Trial in Pyoderma Gangrenosum Selected for Late-Breaker Oral Presentation at 2022 AAD Annual Meeting
Mar 08, 2022
Download PDF read more
InflaRx Provides Update on Development Plans for Vilobelimab in Hidradenitis Suppurativa
Feb 28, 2022
Download PDF read more
InflaRx Reports Progress in Ongoing Phase II Clinical Trial with Vilobelimab in Cutaneous Squamous Cell Carcinoma
Feb 16, 2022
Download PDF read more
InflaRx to Present at Annual SVB Leerink Global Health Conference
Feb 08, 2022
Download PDF read more
InflaRx Announces New Pipeline Program – Oral C5aR Inhibitor Home Investors Press Releases InflaRx Announces New Pipeline Program – Oral C5aR Inhibitor
Jan 10, 2022
Download PDF read more
InflaRx Initiates Phase III Clinical Program with Vilobelimab in Hidradenitis Suppurativa
Jan 05, 2022
Download PDF read more
InflaRx Announces Presentation at J.P. Morgan Healthcare Conference and Other Investor Events
Jan 05, 2022
Download PDF read more
InflaRx Announces Positive Data from Phase II IXCHANGE Study with Vilobelimab in ANCA-associated Vasculitis (AAV)
Nov 15, 2021
Download PDF read more
InflaRx to Present at H.C. Wainwright 7th Annual Israel Conference
Nov 11, 2021
Download PDF read more
InflaRx to Present at the Credit Suisse 30th Annual Healthcare Conference
Nov 03, 2021
Download PDF read more
InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum
Oct 27, 2021
Download PDF read more
InflaRx Awarded up to EUR 43.7 Million (~USD 50.7 Million) Grant by German Government to Advance the Development of Vilobelimab for Treatment of Severe COVID-19
Oct 19, 2021
Download PDF read more
InflaRx Completes Enrollment of Vilobelimab Phase III Study in Severe COVID-19
Oct 12, 2021
Download PDF read more
InflaRx to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Sep 09, 2021
Download PDF read more
InflaRx to Proceed with Pivotal Development for Vilobelimab in Hidradenitis Suppurativa with New Primary Endpoint
Sep 08, 2021
Download PDF read more
InflaRx Announces Positive Data from Second Interim Analysis of Ongoing Phase IIa Open Label Study with Vilobelimab in Pyoderma Gangraenosum
Aug 10, 2021
Download PDF read more
InflaRx to Present at the BTIG Virtual Biotechnology Conference
Aug 06, 2021
Download PDF read more
InflaRx Reports Second Quarter 2021 Financial & Operating Results
Aug 05, 2021
Download PDF read more
InflaRx to Present at the Raymond James Human Health Innovation Conference
Jun 17, 2021
Download PDF read more
InflaRx Doses First Patient in Multicenter Phase II Clinical Trial in Cutaneous Squamous Cell Carcinoma with Vilobelimab
Jun 08, 2021
Download PDF read more
Tony Gibney Joins InflaRx Board of Directors
May 21, 2021
Download PDF read more
InflaRx Reports First Quarter 2021 Financial & Operating Results
May 12, 2021
Download PDF read more
InflaRx Announces Positive Topline Results for Vilobelimab from the U.S. Phase II ANCA-Associated Vasculitis IXPLORE Study
May 11, 2021
Download PDF read more
InflaRx Completes Enrollment of Vilobelimab Phase IIa Study in Pyoderma Gangraenosum
Apr 15, 2021
Download PDF read more
InflaRx Reports Full Year 2020 Financial & Operating Results
Mar 25, 2021
Download PDF read more
InflaRx to Present at Upcoming Investor Conferences
Mar 03, 2021
Download PDF read more
InflaRx Announces Closing of $75 Million Public Offering of Common Shares and One-Year Warrants
Mar 01, 2021
Download PDF read more
InflaRx Announces Pricing of $75 Million Public Offering of Common Shares and One-Year Warrants
Feb 25, 2021
Download PDF read more
InflaRx-Announces-Proposed-Offering-of-Common-Shares-and-One-Year-Warrants
Feb 24, 2021
Download PDF read more
InflaRx Announces Presentation of New C5a and Vilobelimab (IFX-1) Data from Phase IIB SHINE Study at the 2021 Virtual European Hidradenitis Suppurativa Foundation Conference
Feb 11, 2021
Download PDF read more
InflaRx Provides Update on Vilobelimab (IFX-1) Development
Jan 11, 2021
Download PDF read more
InflaRx to Present at Upcoming Annual J.P. Morgan Healthcare Conference
Jan 07, 2021
Download PDF read more
InflaRx Completes Enrollment in Vilobelimab (IFX-1) European Phase II Study in ANCA-associated Vasculitis
Jan 05, 2021
Download PDF read more
InflaRx Reports Q3 2020 Financial & Operating Results
Oct 29, 2020
Download PDF read more

See also in Investors: